Earnings Preview | Ascentage Pharma reports ahead of Thursday's open — pricing and cost discipline matter more than the lossEarnings Preview·Nov 18, 2026 at 10:04 AM06855-3.12%
CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross marginQuartr·Nov 18, 2026 at 06:51 AM01093+1.20%
CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key CatalystAASTOCKS News·Nov 18, 2026 at 05:48 AM09926-4.68%
CSPC Reports Nine-Month Revenue and Profit Growth in 2026Tip Ranks·Nov 18, 2026 at 04:38 AM01093+1.20%
CSPC Pharmaceutical Group: AstraZeneca licence income and finished-drug growth lifted 9M revenue 27% and profit 101.5%Quartr·Nov 18, 2026 at 04:14 AM01093+1.20%
Ascentage Pharma: Lisaftoclax and olverembatinib anchor a pivotal global-readout pushQuartr·Nov 17, 2026 at 11:53 AMAAPG-0.68%06855-3.12%
Daiwa Cuts AKESO TP to HKD120, Reiterates Buy; Decline Exceeds FundamentalsAASTOCKS News·Nov 17, 2026 at 07:58 AM09926-4.68%
CMB International Securities Keeps Their Buy Rating on Akeso, Inc. (9926)Tip Ranks·Nov 17, 2026 at 05:15 AM09926-4.68%